On September 24th and 25th, our CEO, David Blánquez, was present at the second ASEBIO Investor Day.

ASEBIO Investor Day is an event that allows us to present innovative Spanish biotechnology projects to an audience of leading investors and pharmaceutical companies. The event is organized by ASEBIO, the Spanish Bioindustry Association, the Spanish Biotechnology Platform supported by the Spanish Ministry of Science, Innovation and Universities, the support of ICEX – the Spanish Foreign Trade Institute and the Spanish Stock Exchange – MAB Alternative Market.

During the two days we have had more than 15 meetings with different investors to whom we have explained our project to help people with epilepsy and transmitted what our financial needs will be for the coming months.

At MJN we are committed to our mission: to create a technological aid to improve the quality of life of people with epilepsy.

As we are developing a medical device, MJN will not be able to obtain income from its commercialization until the European certificates authorizing it are obtained. It is for this reason that within our activities, the search for financial resources to ensure the viability of MJN is a priority. These include private investment, public subsidies, prizes and private recognitions.

We are working very intensively to obtain the latest certifications that will allow us to start marketing the product, but we estimate that it will still take several months for this to be possible.

We also continue to expand globally; in the coming months we will begin our activities in the United States. We are preparing the participation of MJN in different concept tests in hospitals in that country. Along with that, we are initiating the regulatory process with which our solution may also become a reality in the United States over the next few years. The same as in Europe, this process can last up to 12 months.

At MJN we are committed to our mission: to create a technological aid to improve the quality of life of people with epilepsy.

Leave a Reply

El usuario que cumplimenta la información requerida en el presente formulario declara estar legitimado para ello y se hace responsable exclusivo de la veracidad e integridad de los datos e información que introduce, exonerando expresamente a MJN NEUROSERVEIS de cualquier responsabilidad que pudiera generarse para esta entidad con ocasión de la información facilitada a través del presente formulario.

Sí, acepto

Save the date

The next Saturday 21st of November at 4 pm, you will be able to know first hand our product: mjn-SERAS.
mjn-SERAS is a healthcare product that sends a warning signal when the risk of epileptic seizures is high, to the affected person and their trusted contacts.

Sign up now!


    mjn-SERAS is a medical device with CE marking according to the European Directive 93/42/EEC and the Royal Decree RD. 1591/2009.
    Contraindications: Do not use the product if you suffer from an infection in the ear canal or if you suffer from a skin lesion in the vicinity of the product's area of influence.
    Considerations: This medical product works with an APP only on Android phones. The results tested are 96% sensitivity and 94% specificity.
    CPSP20103CAT.

    Save the date

    El próximo sábado 21 de noviembre a las 4 de la tarde, podrás conocer de primera mano nuestro producto: mjn-SERAS.
    mjn-SERAS es un producto sanitario que lanza una señal de aviso cuando el riesgo de crisis de epilepsia es elevado, a la persona afectada y a sus contactos de confianza.

    ¡Inscríbete!

      mjn-SERAS es un producto sanitario con marcado CE conforme a la Directiva Europea 93/42/EEC y el Real Decreto RD. 1591/2009.
      Contraindicaciones: No usar el producto en caso de padecer una infección en el canal auditivo o en caso de padecer una lesión cutánea en las proximidades del área de influencia del producto.
      Consideraciones: Este producto sanitario funciona con una APP solo en teléfonos Android. Los resultados testeados son 96% de sensibilidad y 94% de especificidad.
      CPSP20103CAT.